Clinical results of definitive-dose (50Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491062 | ||
| 003 | CHVBK | ||
| 005 | 20210128100508.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0736-9 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0736-9 | ||
| 245 | 0 | 0 | |a Clinical results of definitive-dose (50Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer |h [Elektronische Daten] |c [Kazuki Ishikawa, Kiyoshi Nakamatsu, Osamu Shiraishi, Takushi Yasuda, Yasumasa Nishimura] |
| 520 | 3 | |a Background: The clinical results of definitive-dose preoperative chemoradiotherapy (CRT) of 50Gy/25 fractions/5weeks for unresectable esophageal cancer were analyzed. Methods: Inclusion criteria were unresectable esophageal squamous cell carcinoma with T4b or mediastinal lymph nodes invading to the trachea or aorta. Radiation therapy of 50Gy/25 fractions/5weeks was combined concurrently with two courses of FP therapy (CDDP 70mg/m2+5-FU 700mg/m2/d×5days: day 1-5, day 29-33). Tumor response was evaluated 4weeks after completion of RT. Subtotal esophagectomy was planned 6-8weeks after RT. Results: Thirty patients (26 male and 4 female) aged from 50−78years (median 66) were enrolled between 2008 and 2011. The clinical stages according to the 7th edition of UICC were stages II/III/IV, 1/23/6; T1/2/3/4, 1/1/4/24; and N0/1/2/3, 3/25/1/1. All 30 patients completed RT of 50Gy/25 fractions. Initial tumor responses were 21 patients with resectable disease, 7 with unresectable disease, and 2 with progressive disease. Subtotal esophagectomy was performed in 18 (60%) of the 30 patients. Pathological complete response was obtained in five (28%) patients. There were two patients with hospitalization death after surgery (11%). Six of the 7 patients who still had unresectable disease were treated with 1-3 courses of docetaxel, CDDP and 5-FU. Three patients treated without surgery showed long-term survival. The 3-year loco-regional control rate and the 3-year overall survival rate for the 30 patients were 70 and 49%, respectively. Conclusions: Definitive-dose preoperative CRT was feasible, and is a promising treatment strategy for unresectable esophageal cancer. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Unresectable esophageal cancer |2 nationallicence | |
| 690 | 7 | |a Preoperative treatment |2 nationallicence | |
| 690 | 7 | |a Chemoradiotherapy |2 nationallicence | |
| 700 | 1 | |a Ishikawa |D Kazuki |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | |
| 700 | 1 | |a Nakamatsu |D Kiyoshi |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | |
| 700 | 1 | |a Shiraishi |D Osamu |u Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan |4 aut | |
| 700 | 1 | |a Yasuda |D Takushi |u Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan |4 aut | |
| 700 | 1 | |a Nishimura |D Yasumasa |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 531-537 |x 1341-9625 |q 20:3<531 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0736-9 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0736-9 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ishikawa |D Kazuki |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nakamatsu |D Kiyoshi |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shiraishi |D Osamu |u Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yasuda |D Takushi |u Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nishimura |D Yasumasa |u Department of Radiation Oncology, Kinki University Faculty of Medicine, Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 531-537 |x 1341-9625 |q 20:3<531 |1 2015 |2 20 |o 10147 | ||